297 related articles for article (PubMed ID: 21629993)
1. Prevention of hepatitis B virus reactivation in immunosuppressive therapy or chemotherapy.
Ohishi W; Chayama K
Clin Exp Nephrol; 2011 Oct; 15(5):634-640. PubMed ID: 21629993
[TBL] [Abstract][Full Text] [Related]
2. Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy.
Kusumoto S; Tanaka Y; Ueda R; Mizokami M
J Gastroenterol; 2011 Jan; 46(1):9-16. PubMed ID: 20924616
[TBL] [Abstract][Full Text] [Related]
3. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy.
Niitsu N; Hagiwara Y; Tanae K; Kohri M; Takahashi N
J Clin Oncol; 2010 Dec; 28(34):5097-100. PubMed ID: 20837949
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study.
Seto WK; Chan TS; Hwang YY; Wong DK; Fung J; Liu KS; Gill H; Lam YF; Lie AK; Lai CL; Kwong YL; Yuen MF
J Clin Oncol; 2014 Nov; 32(33):3736-43. PubMed ID: 25287829
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.
Kim SJ; Hsu C; Song YQ; Tay K; Hong XN; Cao J; Kim JS; Eom HS; Lee JH; Zhu J; Chang KM; Reksodiputro AH; Tan D; Goh YT; Lee J; Intragumtornchai T; Chng WJ; Cheng AL; Lim ST; Suh C; Kwong YL; Kim WS
Eur J Cancer; 2013 Nov; 49(16):3486-96. PubMed ID: 23910494
[TBL] [Abstract][Full Text] [Related]
6. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma.
Cho Y; Yu SJ; Cho EJ; Lee JH; Kim TM; Heo DS; Kim YJ; Yoon JH
J Med Virol; 2016 Jun; 88(6):1010-7. PubMed ID: 26531242
[TBL] [Abstract][Full Text] [Related]
7. Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection.
Yang HC; Tsou HH; Pei SN; Chang CS; Chen JH; Yao M; Lin SJ; Lin J; Yuan Q; Xia N; Liu TW; Chen PJ; Cheng AL; Hsu C;
J Hepatol; 2018 Aug; 69(2):286-292. PubMed ID: 29551710
[TBL] [Abstract][Full Text] [Related]
8. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B surface antigen seroconversion after HBV reactivation in non-Hodgkin's lymphoma.
Liu WP; Zheng W; Song YQ; Ping LY; Wang GQ; Zhu J
World J Gastroenterol; 2014 May; 20(17):5165-70. PubMed ID: 24803836
[TBL] [Abstract][Full Text] [Related]
10. Reactivation of hepatitis B virus infection in patients with hemo-lymphoproliferative diseases, and its prevention.
Sagnelli C; Pisaturo M; Calò F; Martini S; Sagnelli E; Coppola N
World J Gastroenterol; 2019 Jul; 25(26):3299-3312. PubMed ID: 31341357
[TBL] [Abstract][Full Text] [Related]
11. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.
Huang YH; Hsiao LT; Hong YC; Chiou TJ; Yu YB; Gau JP; Liu CY; Yang MH; Tzeng CH; Lee PC; Lin HC; Lee SD
J Clin Oncol; 2013 Aug; 31(22):2765-72. PubMed ID: 23775967
[TBL] [Abstract][Full Text] [Related]
12. Reactivation of resolved hepatitis B virus infection after immunosuppression: is it time to adopt pre-emptive therapy?
Papamichalis P; Alexiou A; Boulbou M; Dalekos GN; Rigopoulou EI
Clin Res Hepatol Gastroenterol; 2012 Feb; 36(1):84-93. PubMed ID: 21920838
[TBL] [Abstract][Full Text] [Related]
13. Updates on management strategies of hepatitis B virus reactivation in patients with resolved hepatitis virus B infection undergoing immunosuppressive therapy in rheumatology and the current situation in Niigata Rheumatic Center.
Ito S
Mod Rheumatol; 2021 Jul; 31(4):775-782. PubMed ID: 33021133
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
Yeo W; Chan TC; Leung NW; Lam WY; Mo FK; Chu MT; Chan HL; Hui EP; Lei KI; Mok TS; Chan PK
J Clin Oncol; 2009 Feb; 27(4):605-11. PubMed ID: 19075267
[TBL] [Abstract][Full Text] [Related]
15. Reactivation of occult hepatitis B virus infection following cytotoxic lymphoma therapy in an anti-HBc negative patient.
Feeney SA; McCaughey C; Watt AP; Agnaf MR; McDougall N; Wend UC; Gerlich WH; Coyle PV
J Med Virol; 2013 Apr; 85(4):597-601. PubMed ID: 23359331
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy.
Su YC; Lin PC; Yu HC; Wu CC
Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):925-929. PubMed ID: 29621049
[TBL] [Abstract][Full Text] [Related]
17. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma.
Matsue K; Kimura S; Takanashi Y; Iwama K; Fujiwara H; Yamakura M; Takeuchi M
Cancer; 2010 Oct; 116(20):4769-76. PubMed ID: 20597091
[TBL] [Abstract][Full Text] [Related]
18. Risk of hepatitis B reactivation in hepatitis B surface antigen seronegative and core antibody seropositive kidney transplant recipients.
Querido S; Weigert A; Adragão T; Rodrigues L; Jorge C; Bruges M; Machado D
Transpl Infect Dis; 2019 Feb; 21(1):e13009. PubMed ID: 30295412
[TBL] [Abstract][Full Text] [Related]
19. Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy.
Viganò M; Mangia G; Lampertico P
Expert Opin Biol Ther; 2014 Jul; 14(7):1019-31. PubMed ID: 24909454
[TBL] [Abstract][Full Text] [Related]
20. Reactivation of hepatitis B virus in patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma.
Matsui T; Kang JH; Nojima M; Tomonari A; Aoki H; Yamazaki H; Yane K; Tsuji K; Andoh S; Andoh S; Sakai H; Maemori M; Maguchi H; Tanaka Y
J Med Virol; 2013 Nov; 85(11):1900-6. PubMed ID: 23926082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
